CL2020003163A1 - Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidina-2,4-diona y sus sales - Google Patents
Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidina-2,4-diona y sus salesInfo
- Publication number
- CL2020003163A1 CL2020003163A1 CL2020003163A CL2020003163A CL2020003163A1 CL 2020003163 A1 CL2020003163 A1 CL 2020003163A1 CL 2020003163 A CL2020003163 A CL 2020003163A CL 2020003163 A CL2020003163 A CL 2020003163A CL 2020003163 A1 CL2020003163 A1 CL 2020003163A1
- Authority
- CL
- Chile
- Prior art keywords
- disease
- thiazolidine
- dione
- ethoxy
- disorder
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 title 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- JMLKLMFMQRAJNI-UHFFFAOYSA-N 5-[[4-[2-(5-acetylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N1=CC(C(=O)C)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 JMLKLMFMQRAJNI-UHFFFAOYSA-N 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000012268 mitochondrial disease Diseases 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 abstract 1
- 201000005746 Pituitary adenoma Diseases 0.000 abstract 1
- 206010061538 Pituitary tumour benign Diseases 0.000 abstract 1
- 206010036049 Polycystic ovaries Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000021310 pituitary gland adenoma Diseases 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
- 210000001685 thyroid gland Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382402 | 2018-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020003163A1 true CL2020003163A1 (es) | 2021-07-02 |
Family
ID=62716011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020003163A CL2020003163A1 (es) | 2018-06-06 | 2020-12-04 | Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidina-2,4-diona y sus sales |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20210228558A1 (enExample) |
| EP (1) | EP3801517A1 (enExample) |
| JP (1) | JP7510170B2 (enExample) |
| KR (1) | KR20210031867A (enExample) |
| CN (1) | CN112823004A (enExample) |
| AU (1) | AU2019283650A1 (enExample) |
| BR (1) | BR112020024939A2 (enExample) |
| CA (1) | CA3102584A1 (enExample) |
| CL (1) | CL2020003163A1 (enExample) |
| EA (1) | EA202092954A1 (enExample) |
| IL (1) | IL279186A (enExample) |
| MX (1) | MX2020013182A (enExample) |
| SG (1) | SG11202012095XA (enExample) |
| WO (1) | WO2019234690A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| MX2020013181A (es) | 2018-06-06 | 2021-02-26 | Minoryx Therapeutics S L | Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona. |
| HUE071482T2 (hu) | 2018-06-06 | 2025-08-28 | Minoryx Therapeutics S L | (5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra |
| CN116390725A (zh) * | 2020-04-30 | 2023-07-04 | 米尼奥尔克斯治疗有限公司 | 用于治疗肺部炎症和间质性肺病的羟基吡格列酮 |
| WO2022243435A1 (en) * | 2021-05-19 | 2022-11-24 | Abliva Ab | Kl1333 for use in medicine |
| WO2024231881A2 (en) * | 2023-05-09 | 2024-11-14 | Minoryx Therapeutics S.L. | Polymorphic forms and formulations of leriglitazone |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3579049B2 (ja) | 1992-04-30 | 2004-10-20 | インスティチュート・パスツール | Ｍｙｃｏｂａｃｔｅｒｉｕｍ ｔｕｂｅｒｃｕｌｏｓｉｓにおける抗生物質耐性の迅速検出法 |
| GB0030845D0 (en) * | 2000-12-18 | 2001-01-31 | Smithkline Beecham Plc | Novel treatment |
| GB0510469D0 (en) * | 2005-05-23 | 2005-06-29 | Leuven K U Res & Dev | Insulin sensitization to slow down pubertal tempo and to augment pubertal growth |
| AU2012203941A1 (en) * | 2006-06-27 | 2012-07-26 | Sandoz Ag | New method for salt preparation |
| EP2436381A1 (en) * | 2006-06-27 | 2012-04-04 | Sandoz AG | Crystallization of hydrohalides of pharmaceutical compounds |
| WO2013040419A1 (en) * | 2011-09-14 | 2013-03-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| CA2941562C (en) | 2013-03-14 | 2021-09-21 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| NZ725492A (en) | 2014-04-02 | 2023-06-30 | Minoryx Therapeutics S L | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| WO2017083739A1 (en) * | 2015-11-13 | 2017-05-18 | The Trustees Of Columbia University In The City Of New York | A method for predicting a subject's response to valproic acid therapy |
| CN110198945B (zh) | 2016-12-23 | 2023-06-27 | 米尼奥尔克斯治疗有限公司 | 用于制备噻唑烷二酮化合物及其盐的方法 |
-
2019
- 2019-06-06 MX MX2020013182A patent/MX2020013182A/es unknown
- 2019-06-06 AU AU2019283650A patent/AU2019283650A1/en not_active Abandoned
- 2019-06-06 SG SG11202012095XA patent/SG11202012095XA/en unknown
- 2019-06-06 EP EP19742913.7A patent/EP3801517A1/en active Pending
- 2019-06-06 CA CA3102584A patent/CA3102584A1/en active Pending
- 2019-06-06 KR KR1020207037942A patent/KR20210031867A/ko not_active Abandoned
- 2019-06-06 BR BR112020024939-4A patent/BR112020024939A2/pt not_active Application Discontinuation
- 2019-06-06 EA EA202092954A patent/EA202092954A1/ru unknown
- 2019-06-06 US US16/972,366 patent/US20210228558A1/en not_active Abandoned
- 2019-06-06 JP JP2020567972A patent/JP7510170B2/ja active Active
- 2019-06-06 WO PCT/IB2019/054744 patent/WO2019234690A1/en not_active Ceased
- 2019-06-06 CN CN201980046666.1A patent/CN112823004A/zh active Pending
-
2020
- 2020-12-03 IL IL279186A patent/IL279186A/en unknown
- 2020-12-04 CL CL2020003163A patent/CL2020003163A1/es unknown
-
2023
- 2023-09-01 US US18/460,197 patent/US20240091210A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3102584A1 (en) | 2019-12-12 |
| MX2020013182A (es) | 2021-02-26 |
| EA202092954A1 (ru) | 2021-04-08 |
| JP2021527061A (ja) | 2021-10-11 |
| SG11202012095XA (en) | 2021-01-28 |
| WO2019234690A1 (en) | 2019-12-12 |
| IL279186A (en) | 2021-01-31 |
| BR112020024939A2 (pt) | 2021-03-09 |
| AU2019283650A1 (en) | 2021-01-07 |
| US20240091210A1 (en) | 2024-03-21 |
| CN112823004A (zh) | 2021-05-18 |
| JP7510170B2 (ja) | 2024-07-03 |
| KR20210031867A (ko) | 2021-03-23 |
| EP3801517A1 (en) | 2021-04-14 |
| US20210228558A1 (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092954A1 (ru) | Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей | |
| MX379710B (es) | 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-tiazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico. | |
| Goodwani et al. | Metabotropic and ionotropic glutamate receptors as potential targets for the treatment of alcohol use disorder | |
| Zhao et al. | Carnosol-mediated Sirtuin 1 activation inhibits Enhancer of Zeste Homolog 2 to attenuate liver fibrosis | |
| HRP20211032T1 (hr) | Postupci za uporabu agonista fxr | |
| BR112018000212A2 (pt) | uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer | |
| MX390954B (es) | Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| AR106582A1 (es) | Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos | |
| CL2016002517A1 (es) | Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica. | |
| AR108317A1 (es) | Composiciones que comprenden coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
| AR105493A1 (es) | Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h | |
| PE20141822A1 (es) | Inhibidor de la quinasa reguladora de la senal de apoptosis | |
| RU2019100221A (ru) | Составы на основе антитела к CD19 | |
| EA202091120A2 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
| MA39443A1 (fr) | Nouvelle formulation de méloxicam | |
| EP3402480A4 (en) | COMPOSITIONS AND METHODS FOR INTRAVENOUS ADMINISTRATION OF 2-BROMO-1- (3,3-DINITROAZETIDIN-1-YL) ETHANONE | |
| PT3866767T (pt) | Composição farmacêutica para administração oral que inclui um derivado de aminopirimidina ou o seu sal | |
| BR112018011154A2 (pt) | dispersões sólidas compreendendo um estimulador de sgc | |
| EP3442503A4 (en) | INJECTABLE COMPOSITION FOR THE ADMINISTRATION OF A BIOLOGICAL ACTIVE SUBSTANCE | |
| EA201892525A1 (ru) | Конструкции днк-антител для применения против pseudomonas aeruginosa | |
| RU2017114596A (ru) | Лечение жировой болезни печени с применением антагонистов глюкокортикоидных и минералокортикоидных рецепторов | |
| EA201692469A1 (ru) | Производное 2-ациламинотиазола или его соль | |
| CL2020003162A1 (es) | Método de administración de una cantidad terapéuticamente efectiva de 5-[[4-[2-[5-(1- hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona | |
| EA201370162A1 (ru) | Новая фармацевтическая композиция со слабым побочным эффектом, включающая противотуберкулезные препараты | |
| AR109809A1 (es) | Métodos para el uso de agonistas de fxr |